Promising data on Gilead Sciences Inc.’s experimental antiviral remdesivir given as compassionate use to more than 50 hospitalized COVID-19 patients is unlikely to change current clinical trials or clinical care.
That’s largely due to the limitations of the uncontrolled data in a disease where most patients will improve over time, along with the rapid conclusion expected of already
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?